Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

BACKGROUND: In addition to the increased risk for cardiovascular (CV) disease and CV events associated with migraine, patients with migraine can also present with a number of CV risk factors (CVRFs). Existing treatment options can be limited due to contraindications, increased burden associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Robert E., Hochstetler, Helen M., Dennehy, Ellen B., Khanna, Rashna, Doty, Erin Gautier, Berg, Paul H., Starling, Amaal J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734241/
https://www.ncbi.nlm.nih.gov/pubmed/31464581
http://dx.doi.org/10.1186/s10194-019-1044-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734241/
https://www.ncbi.nlm.nih.gov/pubmed/31464581
http://dx.doi.org/10.1186/s10194-019-1044-6

Ejemplares similares